Biogen (NASDAQ:BIIB) Issues FY 2026 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 12.000-13.000 for the period, compared to the consensus estimate of 13.450. The company issued revenue guidance of -, compared to the consensus revenue estimate of $10.1 billion.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BIIB. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and upped their price target for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Argus raised Biogen to a “hold” rating in a report on Thursday, April 9th. Sanford C. Bernstein reduced their target price on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. The Goldman Sachs Group upped their target price on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Finally, Rothschild & Co Redburn increased their target price on shares of Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Biogen has an average rating of “Moderate Buy” and an average target price of $220.57.

Biogen Stock Up 2.7%

NASDAQ BIIB opened at $205.61 on Wednesday. The firm has a market cap of $30.36 billion, a PE ratio of 22.06 and a beta of 0.16. Biogen has a one year low of $124.56 and a one year high of $219.72. The stock’s 50 day simple moving average is $200.25 and its 200 day simple moving average is $190.21. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts forecast that Biogen will post 11.28 earnings per share for the current fiscal year.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of approximately $2.74 billion, up 3% year over year and ahead of the $2.46 billion analyst consensus. Adjusted EPS of $3.60 also exceeded expectations of $2.94. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: The Growth Portfolio generated $1.06 billion in revenue, up 24% year over year and surpassing the legacy multiple-sclerosis portfolio. Key contributions included SKYCLARYS revenue of $168 million, ZURZUVAE revenue of $71 million, and post-acquisition sales from Apellis products SYFOVRE and EMPAVELI. Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs
• Positive Sentiment: Biogen expects 2026 revenue to increase by a mid-single-digit percentage, suggesting continued momentum from newer rare-disease and specialty medicines as older multiple-sclerosis products decline.
• Neutral Sentiment: The company completed its acquisition of Apellis, adding SYFOVRE and EMPAVELI to its commercial portfolio. The deal expands Biogen’s growth prospects but also introduces integration and execution risks.
• Negative Sentiment: GAAP net income fell to $97.5 million from $634.8 million a year earlier, while GAAP diluted EPS was $0.66. The decline highlights the impact of costs and other charges despite the adjusted earnings beat.
• Negative Sentiment: Biogen set full-year 2026 adjusted EPS guidance at $12.00-$13.00, below the $13.45 analyst consensus. The lower outlook is the main potential pressure on BIIB, even though quarterly results exceeded estimates. Biogen Cuts FY Adjusted View as Profit Declines

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Strive Financial Group LLC bought a new stake in Biogen during the 4th quarter worth about $35,000. DV Equities LLC bought a new position in shares of Biogen in the fourth quarter worth about $36,000. Meeder Asset Management Inc. raised its stake in shares of Biogen by 323.5% in the fourth quarter. Meeder Asset Management Inc. now owns 216 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 165 shares during the last quarter. Summit Securities Group LLC lifted its position in shares of Biogen by 346.9% during the fourth quarter. Summit Securities Group LLC now owns 219 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 170 shares in the last quarter. Finally, WFA of San Diego LLC acquired a new position in shares of Biogen during the second quarter worth approximately $32,000. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.